3.6.2 A seguito di quanto espresso

3.6.2 A seguito di quanto espresso al punto precedente, verrà presentata all’approvazione del Comitato Etico Sperimentazioni la terapia per gruppi di patologie tra loro somiglianti (malattie metaboliche da accumulo, malattie neurologiche autoimmuni, malat-tie autoimmuni, epilessie, malattie neurodegenerative). Per gruppi di patologie verrà realizzata, in collaborazione con la Clinica, una bibliografia di supporto alla decisione di trattamento.
La casistica dei pazienti dopo i primi 4/6 mesi di attività, sarà raggruppata per pato-logie in modo da formare banche dati omogenee.

Results (English) 1:

3.6.2 following as expressed in the previous paragraph, will be presented for approval by the Ethics Committee for therapy Trials groups together similar disease (glycogen storage diseases, metabolic, neurological, autoimmune DIS-tie, epilepsy, autoimmune neurodegenerative diseases). For groups of diseases will be carried out, in cooperation with the clinic, a bibliography of treatment decision support. Case studies of patients after the first 4/6 months, will be grouped for pato-logie to form homogeneous databases.

Results (English) 2:

3.6.2 Following the statement in the previous paragraph, will be presented to the Committee of Ethics Trials therapy for groups of diseases among their similar (metabolic diseases by accumulation, autoimmune neurological diseases, autoimmune malat-tie, epilepsy, neurodegenerative diseases) . For groups of diseases will be implemented in partnership with the Clinic, a bibliography to support the treatment decision.
The case histories of patients after the first 6.4 months of activity, will be grouped by pato-nologies to form databases homogeneous.

Results (English) 3:

3.6.2 AS A result of the expressed in the previous paragraph, will be submitted to the approval of the Ethics Committee experimentations, the therapy for disease groups between their closely resembling (metabolic diseases by accumulation, neurological diseases, autoimmune disease-tie autoimmune, epilepsy and neurodegenerative diseases). For groups of diseases will be realized, in collaboration with the Clinic,A bibliography to support the treatment decision.
The case histories of patients after the first 4/6 months activity and will be grouped for pato-logie in such a way as to form banks homogeneous data.